AEG 35156

Drug Profile

AEG 35156

Alternative Names: AEG 161; AEG35156; GEM® 640

Latest Information Update: 29 Jul 2015

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Aegera Therapeutics
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; B cell lymphoma; Breast cancer; Chronic lymphocytic leukaemia; Hepatocellular carcinoma; Multiple sclerosis; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 12 Jul 2011 Aegera Therapeutics terminates phase I/II trial in Chronic lymphocytic leukaemia and B-cell lymphoma in USA and Canada NCT00768339)
  • 27 May 2011 Aegera Therapeutics has been acquired by Pharmascience
  • 19 Jul 2010 Efficacy and adverse events data from a phase I/II trial in Hepatocellular carcinoma released by Aegera Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top